

SYNERGIA MEDICAL INCREASES SERIES B FUNDING TO €12.8 MILLION WITH AN ADDITIONAL €3.8 MILLION

Synergia Medical announced the completion of an additional €3.8 million of Series B funding, allowing the preparation for FIH clinical trials planned for 2024

BELGIUM, January 18, 2023 /EINPresswire.com/ -- Synergia Medical, a preclinical medical device



I believe that Synergia Medical's epilepsy treatment has huge potential and I am delighted to help finance their development, it has the potential to bring quality of life improvements to patients."

Jacques Berrebi

company that has developed NAO.VNS (Vagus Nerve Stimulation), the first non-metal optoelectronic neurostimulator for the treatment of drug-resistant epilepsy, today announced the successful completion of an additional €3.8 million of Series B funding bringing the total to €12.8 million. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2024.

This additional financing was realized with a pool of investors: Invest BW, the investment and financing company of Walloon Brabant, various private investors from TheClubDeal, and the Berrebi family represented by

Mr Jacques Berrebi. These new investors join the historical private shareholders, Newton Biocapital, TheClubDeal, and public investors (SFPI, SRIW Life Sciences, Investsud).

"I am delighted to welcome our new investors and thank them for the confidence they place in Synergia Medical. Bringing our Vagus Nerve Stimulation treatment to the many epilepsy patients who live in the constant fear and uncertainty of an epileptic seizure is vital and these additional funds reinforce our ability to prepare for our First-In-Human clinical trials in early 2024." declared Attila Borbath, CEO & Co-founder of Synergia Medical.

"I believe that Synergia Medical's epilepsy treatment has huge potential and I am delighted to help them finance their development, which has the potential to bring significant quality of life improvements to epilepsy patients." said Jacques Berrebi, chairman of the investment group Bercom International.

To date, Synergia Medical has raised more than €30 million since 2016. The company has a staff of 27, essentially focused on pre-clinical studies, R&D and expertise in quality and regulatory

affairs. It has a business-oriented Board of Directors with many years of operational health sector experience and a Scientific Advisory Board of world renown experts in neural stimulation and Epilepsy.

About Epilepsy and Drug-Resistant Epilepsy

Epilepsy is the 4th most common neurological disorder after migraine, stroke, and Alzheimer's disease affecting 65 million people worldwide. The conventional medical treatment is with anti-epileptic drugs (AEDs) but 30% of the epileptic population see their symptoms poorly controlled with drugs and continue to have seizures that impair their health and daily life despite medication intake. They are consequently diagnosed with DRE (drug-resistant epilepsy). More than 1.15 million patients are currently waiting for an effective treatment, representing an estimated obtainable market of c.€20 billion.

About NAO.VNS – Optoelectronics for Vagus Nerve Stimulation

NAO.VNS is a new generation metal free neurostimulator that can reduce epileptic seizures by stimulation of the vagus nerve (VNS), by using a new technology of materials to improve patients' life. Optoelectronics send safe, personalized neural stimulation pulses in a magnetic field to the Vagus Nerve. Neural stimulation is a clinically proven solution and the last resort for these patients. It involves the implantation of a small pacemaker connected to leads that deliver mild electric signals to targeted nerves or brain cells. NAO.VNS uses optical fibers and glass cover, instead of metal wires and casing.

About Synergia Medical – www.synergia-medical.com

Synergia Medical is an ISO 13485 certified medical device company that has developed NAO.VNS (Vagus Nerve Stimulation), the first non-metal optoelectronic neurostimulator for the treatment of drug-resistant epilepsy.

Operational since 2015, Synergia Medical is based in Belgium and employs 27 employees. It was co-founded by Attila Borbath, CEO and Pascal Doguet, inventor of NAO.VNS. The company holds a portfolio of 9 patents in 15 families. Synergia Medical is supported by Wallonia Region grants and by European Innovation Council (EIC) through an Accelerator financing.

Contacts

Synergia Medical
Attila Borbath
CEO
+32497404767
info@synergiam.com

Synergia Medical Communications
Orpheon Finance
j.palmer@orpheonfinance.com
+33760927774

Synergia Medical SA
Rue Emile Francqui 6
B-1435 Mont-St-Guibert,
Belgium

James Palmer
Orpheon Finance
+33 7 60 92 77 74
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/611907903>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.